JAZZ - Jazz Pharmaceuticals misses top-line and bottom-line estimates; reaffirms FY24 outlook
2024-05-01 16:23:44 ET
More on Jazz Pharmaceuticals
- Jazz Pharmaceuticals: Cheap But Complicated
- Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
- Avadel surges after royalty rate awarded to Jazz in patent dispute lower than requested (update)